NCT00827632 - Obesity, Oral Contraception, and Ovarian Suppression | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Ovarian Suppression

Interventions

DRUG

Low dose formulation

"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."

DRUG

High dose formulation

"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Columbia University

OTHER